Sharpepoint LLC Has $6.38 Million Stake in Eli Lilly and Company (NYSE:LLY)

Sharpepoint LLC lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 23.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,209 shares of the company's stock after selling 2,220 shares during the quarter. Eli Lilly and Company makes up 5.7% of Sharpepoint LLC's investment portfolio, making the stock its largest holding. Sharpepoint LLC's holdings in Eli Lilly and Company were worth $6,382,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Knightsbridge Asset Management LLC lifted its position in shares of Eli Lilly and Company by 1.9% during the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after buying an additional 15 shares during the period. LS Investment Advisors LLC boosted its stake in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the period. CSM Advisors LLC boosted its holdings in Eli Lilly and Company by 30.6% during the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after purchasing an additional 245 shares during the last quarter. Proficio Capital Partners LLC grew its stake in shares of Eli Lilly and Company by 30.2% in the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock valued at $5,202,000 after buying an additional 1,562 shares in the last quarter. Finally, Bfsg LLC boosted its stake in shares of Eli Lilly and Company by 1.4% during the 1st quarter. Bfsg LLC now owns 2,959 shares of the company's stock worth $2,444,000 after acquiring an additional 42 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

LLY stock traded up $3.31 on Thursday, hitting $790.23. The company had a trading volume of 3,128,711 shares, compared to its average volume of 3,670,296. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The stock has a market cap of $748.93 billion, a price-to-earnings ratio of 64.30, a P/E/G ratio of 1.15 and a beta of 0.40. The stock's 50-day simple moving average is $767.12 and its 200 day simple moving average is $800.05.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company's revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.58 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. Eli Lilly and Company's payout ratio is 48.82%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on LLY shares. Guggenheim reissued a "buy" rating and issued a $936.00 target price on shares of Eli Lilly and Company in a research report on Friday, June 20th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their target price for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. Finally, Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average target price of $1,012.22.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.